Validity analysis of pulmicort respulas combined with montelukast in treating children with asthma and its role in pulmonary function and T lymphocyte subset / 药物评价研究

ABSTRACT

Objective To explore the validity of oxygen atomizing inhalation pulmicort respulas combined with montelukast in treating children with asthma and its role in pulmonary function and T lymphocyte subset.Methods Totally 78 cases treated in Huizhou People's Hospital from June,2014 to June,2016 were randomly divided into observation group and control group with each group of 39 cases.The control group on the basis of routine treatment with oxygen atomizing inhalation of pulmicort 1 mg,twice daily,and the observation group based on control group added Montelukast Sodium Chewable Tablets 5 mg,once daily,one week for one course.The clinical effect,pulmonary function,and level of T lymphocyte subset were compared between two groups.Results The total effective rate in the observation group was 94.70％,which was significantly higher than control group (82.05％,P ＜ 0.05).After therapy,the symptom scores of two groups were obviously decreased compared with those before therapy (P ＜ 0.05),and those of the observation group were significantly lower than control group (P ＜ 0.05);The pulmonary function of the two groups were obviously improved (P ＜ 0.05) compared with that before therapy (P ＜ 0.05),and the levels of FEV1,FVC,and FEV1/FVC in observation group were significantly higher than control group (P ＜ 0.05);The level ofT lymphocyte subset in control group showed no statistical difference compared to that before therapy,and the levels of CD4+ and CD4+/CD8+ in observation group were obviously decreased,whereas CD8+ was increased.Conclusion Oxygen atomizing inhalation pulmicort respulas combined with montelukast could effectively increase the clinical effect on children with asthma,improve pulmonary function and positively regulate immune function,which deserves clinical expansion.